Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to Leishmaniasis

Journal of Immunology

Volumn 160, Issue 8, 1998, Pages 3949-3957

  Sjölander, Anders ^a   Baldwin, Tracey M ^a   Curtis, Joan M ^a   Handman, Emanuela ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DNA, PROTOZOAN; FEMALE; IMMUNOGLOBULIN G; ISCOMS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; PROTOZOAN PROTEINS; SPLEEN; TH1 CELLS; TH2 CELLS; VACCINATION; VACCINES, DNA;

EID: 0344482144     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383:787.
2. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59.
3. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA 88:7011.
4. Erb, K. J., C. Blank, and H. Moll. 1996. Susceptibility to Leishmania major in IL-4 transgenic mice is not correlated with the lack of a Th1 immune response. Immunol. Cell Biol. 74:239.
5. Kopf, M., F. Brombacher, G. Köhler, G. Kienzle, K.-H. Widmann, K. Lefrang, C. Humborg, B. Ledermann, and W. Solbach. 1996. IL-4-deficient BALB/c mice resist infection with Leishmania major. J. Exp. Med. 184:1127.
6. Morris, L., A. B. Troutt, K. S. McLeod, A. Kelso, E. Handman, and T. Aebischer. 1993. Interleukin-4 but not interferon-γ production correlates with the severity of disease in murine cutaneous leishmaniasis. Infect. Immun. 61:3459.
7. + T-cell phenotype development. Proc. Natl. Acad. Sci. USA 92:7565.
8. Kelso, A. 1995. Th1 and Th2 subsets: paradigms lost? Immunol. Today 16:374.
9. + cells correlate with resolution of lesions in murine cutaneous leishmaniasis. J. Immunol. 149:2715.
10. Symons, F. M., P. J. Murray, A. H. Osborn, R. Cappai, and E. Handman. 1994. Characterisation of a polymorphic family of integral membrane proteins in promastigotes of different Leishmania species. Mol. Biochem. Parasitol. 67:103.
11. Handman, E., A. H. Osborn, F. Symons, R. van Driel, and R. Cappai. 1995. The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle. Mol. Biochem. Parasitol. 74:189.
12. Handman, E., F. M. Symons, T. M. Baldwin, J. M. Curtis, and J.-P. Y. Scheerlinck. 1995. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect. Immun. 63:4261.
13. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151.
14. Raz, E., H. Tighe, Y. Sato, M. Corr, J. A. Dudler, M. Roman, S. L. Swain, H. L. Spiegelberg, and D. A. Carson. 1996. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA 93:5141.
15. Xu, D., and F. Y. Liew. 1995. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp 63 of L. major. Immunology 84:173.
16. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137.
17. + T cell responses by oral or parenteral immunization with ISCOMS. Eur. J. Immunol. 25:2835.
18. Morein, B., K. Lövgren, B. Rönnberg, and A. Sjölander. 1995. Immunostimulating complexes: clinical potential in vaccine development. Clin. Immunother. 3:461.
19. Handman, E., R. E. Hocking, G. F. Mitchell, and T. W. Spithill. 1983. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol. Biochem. Parasitol. 7:111.
20. Cruz, A., and S. M. Beverley. 1990. Gene replacement in parasitic protozoa. Nature 348:171.
21. LeBowitz, J. H., C. M. Coburn, D. McMahon-Pratt, and S. M. Beverley. 1990. Development of a stable Leishmania expression vector and application to the study of parasite surface antigens. Prof. Natl. Acad. Sci. USA 87:9736.
22. Morrisey, J. H. 1981. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal. Biochem. 117:307.
23. Murray, P. J., and T. W. Spithill. 1991. Variants of a Leishmania surface antigen derived from a multigenic family. J. Biol. Chem. 266:24477.
24. Rönnberg, B., M. Fekadu, and B. Morein. 1995. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM-matrix. Vaccine 13: 1375.
25. Lövgren, K., and B. Morein. 1988. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol. Appl. Biochem. 10:161.
26. 1 hybrids infected with Leishmania tropica major. J. Immunogenet. 10:395.
27. Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545.
28. Sjölander, A., K. Lövgren-Bengtsson, M. Johansson, and B. Morein. 1996. Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (Iscoms) containing human influenza virus envelope glycoproteins. Scand. J. Immunol. 43:164.
29. Lövgren Bengtsson, K., and A. Sjölander. 1996. Adjuvant activity of iscoms: effect of ratio and co-incorporation of antigen and adjuvant. Vaccine 14:753.
30. Bogdan, C., A. Gessner, W. Solbach, and M. Rollinghoff. 1996. Invasion, control and persistence of Leishmania parasites. Curr. Opin. Immunol. 8:517.
31. Coffman, R. L., D. A. Lebman, and P. Rothman. 1993. Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54:229.
32. Heinzel, F. P., R. M. Rerko, F. Ahmed, and E. Pearlman. 1995. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J. Immunol. 155:730.
33. Scott, P., A. Eaton, W. C. Gause, X.-D. Zhou, and B. Hondowicz. 1996. Early IL-4 production does not predict susceptibility to Leishmania major. Exp. Parasitol. 84:178.
34. Corr, M., D. J. Lee, D. A. Carson, and H. Tighe. 1996. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184:1555.
35. + cytotoxic T cells by immunization with purified HIV-1 envelope proteins in iscoms. Nature 344:873.
36. + T cells secreting Th1 and Th2 cytokines. Immunity 2:271.
37. Locksley, R. M., and J. A. Louis. 1992. Immunology of leishmaniasis. Curr. Opin. Immunol. 4:413.
38. Reiner, S. L., and R. M. Locksley. 1993. The worm and the protozoa: stereotyped responses or distinct antigens? Parasitol. Today 9:258.
39. + cells secreting IL-4. Int. Immunol. 5:761.
40. Handman, E., R. Ceredig, and G. F. Mitchell. 1979. Murine cutaneous leishmaniasis: disease patterns in intact and nude mice of various genotypes and examination of differences between normal and infected macrophages. Aust. J. Exp. Biol. Med. Sci. 57:9.
41. Afonso, L. C. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235.
42. + T cells during initiation of infection. J. Exp. Med. 179:447.
43. + T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178:567.
44. Scharton-Kersten, T., L. C. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154:5320.
45. Villacres-Eriksson, M. 1995. Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin. Exp. Immunol. 102: 46.
46. Villacres-Eriksson, M., S. Behboudi, A. J. Morgan, O. Trinchieri, and B. Morein. 1997. Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin-12 and its effects on the antibody response. Cytokine 9:73.
47. Sjölander, A., B. van't Land, and K. Lövgren Bengtsson. 1997. Iscoms containing purified Quillaja saponins up-regulate both Th1-like and Th2-like immune responses. Cell. Immunol. 177:69.
48. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: evidence for a T cell-dependent, interferon gamma-independent mechanism. J. Exp. Med. 171:115.
49. Wakil, A. E., Z.-E. Wang, and R. M. Locksley. 1996. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection. Exp. Parasitol. 84:214.
50. Donnelly, J. J., J. B. Ulmer, and M. A. Liu. 1994. Immunization with DNA. J. Immunol. Methods 176:145.
51. Wahren, B. 1996. Gene vaccines. Immunotechnology 2:77.
52. + T lymphocytes. J. Immunol. 155:259.
53. Huygen, K., J. Content, O. Denis, D. L. Montgomery, A. M. Yawman, R. R. Deck, C. M. DeWitt, I. M. Orme, S. Baldwin, C. D'Souza, A. Drowart, E. Lozes, P. Vandenbussche, J.-P. Van Vooren, M. A. Liu, and J. B. Ulmer. 1996. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2:892.
54. Tascon, R. E., M. J. Colston, S. Ragno, E. Stavropoulos, D. Gregory, and D. B. Lowrie. 1996. Vaccination against tuberculosis by DNA injection. Nat. Med. 2:888.
55. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249.
56. Flynn, J. L., M. M. Goldstein, K. J. Triebold, B. Koller, and B. R. Bloom. 1992. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. USA 89:12013.
57. Davis, H. L., M. Mancini, M.-L. Michel, and R. G. Whalen. 1996. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine 14:910.
58. Xiang, Z. Q., S. L. Pitalnik, J. Cheng, J. Erikson, B. Wojczyk, and H. C. J. Ertl. 1995. Immune responses to nucleic acid vaccines to rabies virus. Virology 209: 569.